Faron Pharmaceuticals Oy (AIM:FARN) is a clinical stage bio-pharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen®, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Nasdaq (Nasdaq: NDAQ) announces that trading in Faron Pharmaceuticals Oy shares (short name: FARON) commences on December 3, 2019 on Nasdaq First North Growth Market Finland. Sisu Partners served as Certified Advisor for Faron in the transaction, and will continue in the role of Certified Advisor after the transaction.
Sisu Partners
Advised in the sale of
Faron Pharmaceuticals Oy
to